Nathan T. Connell
Harvard University
What is this?
Publications 37
#1Nathan T. Connell (Harvard University)H-Index: 5
#2Elisabeth M. Battinelli (Harvard University)H-Index: 17
Last. Jean-Marie Connors (Harvard University)H-Index: 30
view all 3 authors...
Abstract Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti??2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti??2-glycoprotein I antibodies were reportedly IgG and IgM, although spec...
4 CitationsSource
#1Nathan T. Connell (Brigham and Women's Hospital)H-Index: 5
#1Mohamad A. Kalot (KU: University of Kansas)H-Index: 1
#2Mohammed Al‐Khatib (KU: University of Kansas)H-Index: 1
Last. William C. NicholsH-Index: 48
view all 44 authors...
INTRODUCTION: von Willebrand disease (VWD) is an inherited bleeding disorder caused by a quantitative or qualitative dysfunction of von Willebrand factor. Clinicians, patients and other stakeholders have many questions about the diagnosis and management of the disease. AIM: To identify topics of highest importance to stakeholders that could be addressed by guidelines to be developed by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the N...
1 CitationsSource
#1Nathan T. Connell (Harvard University)H-Index: 5
#1Chi-Joan How (Harvard University)H-Index: 1
#2Orly Leiva (BU: Boston University)H-Index: 5
Last. Annemarie E. Fogerty (Harvard University)H-Index: 7
view all 19 authors...
1 CitationsSource
#1Abigail M. Lee (Yale University)H-Index: 27
#2Leah E. Masselink (GW: George Washington University)H-Index: 8
Last. Clese Erikson (GW: George Washington University)H-Index: 1
view all 6 authors...
#1Leah E. Masselink (Milken Institute)H-Index: 8
#1Leah E. Masselink (Milken Institute)
Last. Abigail M. Lee (Yale University)H-Index: 27
view all 13 authors...
As the adult hematology and oncology fellowship training pathways have merged in the United States and concerns have arisen about the aging of practicing hematologists, the American Society of Hematology and hematology education leaders are looking to improve their understanding of the factors that contribute to fellows’ plans to enter hematology-only careers. With the support of the American Society of Hematology, we collected and analyzed data from a survey of hematology/oncology fellows (n = ...
1 CitationsSource
#1Robert M. Stern (Harvard University)H-Index: 1
#2Nathan T. Connell (Brigham and Women's Hospital)H-Index: 5
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, ...
5 CitationsSource
#1Nathan T. Connell (Harvard University)H-Index: 5
#2J. M. Connors (Harvard University)H-Index: 28
Last. Jean-Marie Connors (Harvard University)H-Index: 30
view all 2 authors...
Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome. The direct oral anticoagulant edoxaban has been shown to be noninferior to dalteparin for the treatment of cancer-associated thrombosis. In a Markov simulation model, edoxaban with 6-month time horizon and a United States societal perspective with 2017 US d...
#1Nahal BeikH-Index: 2
#2Prabashni ReddyH-Index: 5
Last. Jean-Marie ConnorsH-Index: 30
view all 7 authors...
Andexanet alfa, a recombinant modified human “decoy” factor Xa (FXa) protein, is the first and only available antidote approved by the Food and Drug Administration to manage life-threatening or uncontrolled bleeding associated with the anti-Xa agents. It binds to direct and indirect anti-Xa oral ant
1 CitationsSource